About

“The regenerative medicine revolution is upon us.  Like iron and steel to the industrial revolution, like the microchip to the tech revolution, stem cells will be the driving force of this next revolution,” said noted industry watcher Cade Hildreth of BioInformant.  

Axolotl Biologix (AxoBio) is a Phoenix-based biologics company focused on improving the quality of life for people around the world through regenerative medicine using human cells and tissues.

Regenerative medicine technologies offer new, less invasive, less painful and lower cost treatments that will increasingly disrupt and take market share within a wide range of worldwide medical care markets.  Over time, regenerative technologies such as those being created by AxoBio will disrupt and take market share in the $20B wound care, $47B orthopedics, $29B dental consumables and $12B aesthetic medicine markets.  AxoBio has identified an initial market opportunity of $11B comprised just of the key markets for its 2017 and 2018 products that includes the $4B tissue-engineered skin substitute market, $3B soft orthobiologics market and $4B facial rejuvenation market.

Something akin to fertilizing your lawn to get the grass to grow, the company’s first product, AxoBioFLUID® activates the growth of people’s own cells to rejuvenate worn out or damaged tissues, which offers simple injection treatments for joint pain, and ligament and muscle damage.  Some pioneering physicians are finding the product a useful treatment for neurological disorders such as autism.

AxoBio's second product, AxoBioMembraneTM is a dehydrated human amniotic membrane allograft that helps accelerate and improve soft tissue wound repair, while helping inhibit bacteria and infection, inflammation, and scar tissue formation.

AxoBio’s next-gen products, AxoBioECMTM and AxoBioSKINTM provide wound repair with the patient’s own skin that has been grown in a lab from a tiny 5mm sample.  These products build on the company’s two patents for Elastatroepin®, a recombinantly-derived human tropoelastin, to create a novel elastic biomaterial that serves as a biomimetic skin substitute and acts as a delivery vehicle for human cells to a full thickness dermal wound.  These unique, patented products are expected to have a significant impact in the wound care market, especially for diabetes-related chronic wounds, trauma, burn, dental and surgical wounds.